India, Nov. 16 -- Moleculin Biotech, Inc. (MBRX) reported Monday third-quarter 2026 financial results and announced completion of treatment for all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML).
Company Profile
Moleculin Biotech is a clinical-stage pharmaceutical company developing therapies for difficult-to-treat cancers and viral infections. Its lead candidate, Annamycin (naxtarubicin), is being evaluated for relapsed or refractory AML and soft tissue sarcoma lung metastases. The company is also developing WP1066 for brain tumors and other cancers.
Third-Quarter 2026 Financial Results
Research and development expenses increased to approximately ...